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Kathryn B. Garber1,*Exome Sequencing Yields Gene Mutations
for Kabuki Syndrome
Although sought in several investigations, genetic muta-
tions associated with Kabuki syndrome has remained
elusive because of the relative rarity of the syndrome and
the fact that most cases are sporadic, thereby hindering
traditional gene-hunting strategies. This syndrome, which
gets its name from the characteristic facies that are
reminiscent of the makeup used in traditional Japanese
Kabuki theater, is a multiple-malformation syndrome
that includes intellectual disability. With the identification
of MLL2 mutations in patients with Kabuki syndrome,
Ng et al. demonstrate again the power of whole-exome
sequencing for the identification of rare genetic mutations.
Their sample consisted of ten affected individuals of
various ethnic backgrounds. Although their initial analysis
did not yield a probable candidate gene, the allowance for
genetic heterogeneity in their sample, as well as a system
of ranking the individuals in the sample according to
how well their phenotype matched the Kabuki syndrome
gestalt, highlighted MLL2 as a candidate gene. Ultimately,
nine out of ten cases in the initial cohort had inactivating
MLL2 mutations, as did 66% of affected individuals in a
larger sample. Although MLL2 mutations may not be the
only mutations responsible for Kabuki syndrome, they
certainly are a major contribution to this phenotype.
Ng et al. (2010) Nat Genet. Published online August 15,
2010. 10.1038/ng.646.
The PARK2 Tumor Suppressor?
PARK2 is most famously associated with familial Parkinson
disease, the disease from which it gets its name. But dele-
tion of this gene has most recently been linked to the
development of sporadic colorectal cancers (CRCs). Poulo-
giannis et al. were seeking small copy number changes in
sporadic CRCs, and their most frequent hit was deletion
of an approximately 1 Mb region within PARK2, a change
that was found in one-third of the sporadic CRCs. Second-
hit mutation or inactivating methylation of the remaining
PARK2 allele was only infrequently observed, suggesting
that haploinsufficiency, rather than a classic two-hit
model, is sufficient for inactivation of PARK2’s tumor-
suppressing capacity. PARK2 is located at a chromosomal
fragile site, so these deletions might simply be a byproduct
of tumor development, rather than a driver of tumorigen-
esis. However, the authors demonstrate that heterozygous1Department of Human Genetics, Emory University School of Medicine, Atlan
*Correspondence: kgarber@genetics.emory.edu
DOI 10.1016/j.ajhg.2010.08.010. 2010 by The American Society of Human
The Americandeletion of Park2 in mice with a mutation in the CRC-asso-
ciated gene Apc increases the prevalence and accelerates
the development of intestinal adenomas.
Poulogiannis et al. (2010) Proc Natl Acad Sci. Published
online August 9, 2010. 10.1073/pnas.1009941107.
New Congenital Disorder of Glycosylation Caused
by Mutations in an Unexpected Gene
Although N-linked glycosylation is an essential posttrans-
lational modification in eukaryotic cells, the biosynthesis
of its precursors is not fully characterized. In the process
of elucidating the cause of a multisystemic syndrome
that includes congenital eye malformations, cerebellar
atrophy or vermis malformation, microcytic anemia, and
dysmorphic features, Cantagrel et al. better define a crucial
component of N-linked glycosylation that comes from an
unexpected corner. Extensive consanguinity in the orig-
inal family indicated that the disorder was likely to be
autosomal recessive, and linkage analysis followed by
brute-force sequencing uncovered a complex mutation in
SRD5A3, which—on the basis of sequence similarity—
was believed to encode a steroid 5a-reductase. This didn’t
jive with the fact that the phenotype in affected families
was reminiscent of a congenital disorder of glycosylation
and that an early step in N-linked glycosylation was
defective in patient cells. The authors used extensive
biochemical characterization to show that SRD5A3 is
actually a polyprenol reductase that is necessary for
synthesis of the lipid carrier of the oligosaccharide that
will be transferred to proteins in the N-glycosylation
process. An open mind and a willingness to look beyond
homology-based predictions allowed the authors to define
a new congenital disorder of glycosylation and to further
outline the process of N-linked glycosylation.
Cantagrel et al. (2010) Cell 142, 203–217. 10.1016/
j.cell.2010.06.001.
Making the Switch
As a result of developmental regulation, fetal hemoglobin
(HbF) is gradually replaced by HbA and generally makes
up only < 2% of all hemoglobin in an adult. Stimulation
of HbF expression in patients with b-thalassemia alleviates
their anemia and can reduce their dependence on blood
transfusions. However, the pharmacological agents that
have been used to induce HbF expression are not ideal
and can have side effects, such as cytotoxicity andta, GA 30322, USA
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inhibition of erythropoiesis. Two recent papers uncover
a new regulatory mechanism for globin chain switching
that could have implications for this therapeutic approach.
Borg et al. identify mutations in KLF1 in individuals with
hereditary persistence of HbF. This transcription factor is
expressed in erythroid cells and their precursors and is
known to regulate many aspects of erythroid differentia-
tion, including activation of HBB expression. What was
not previously appreciated is that KLF1 also activates
expression of BCL11A, which, in turn, represses expression
of the fetal HBG1/HBG2 genes. Thus, in addition to direct
stimulation of HbA production, KLF1 also indirectly
represses production of HbF. This model is further sup-
ported by the work of Zhou et al., who demonstrate that
in mice, reductions in Klf1 expression increase the relative
production of HbF through reductions in Bcl11a produc-
tion. These experiments outline two potential new targets
for pharmacologic stimulation of HbF production in the
treatment of b-globin disorders.
Borg et al. (2010) Nat Genet. Published online August 1,
2010. 10.1038/ng.630.
Zhou et al. (2010) Nat Genet. Published online August 1,
2010. 10.1038/ng.637.314 The American Journal of Human Genetics 87, 313–314, SeptembLong-Term Survivors of Gene Therapy for SCID
The development of leukemia in childrenwhowere treated
with gene therapy for X-linked severe combined immuno-
deficiency (SCID-X1) was splashy news. What became of
those children and the others who did not develop
leukemia? They are now as far as 11 years out from the gene
therapy treatment, and results of their longer-term follow
up have recently been reported by Hacein-Bey-Abina et al.
Although one child who developed leukemia did succumb
to the disease, seven of the nine children in the study
live normal lives (i.e., not in a bubble) and are growing
normally, including three patients who recovered from
leukemia with chemotherapy. Only one of the eight survi-
vors did not have sustained reconstitution of his immune
system, but three of them do require immunoglobulin-
replacement therapy. Certainly, the fact that almost half
of the children developed leukemia indicates that this
treatment is a risky proposition. However, compare this to
long-term data on survival of individuals with SCID-X1
after hematopoietic stem cell transplant, the current best
treatment. Of those who are transplanted with cells from
a mismatched donor, approximately two-thirds survive.
Hacein-Bey-Abina et al. (2010) NEJM 363, 355–364.This Month in our Sister JournalsEven Classic Mendelian Diseases Are Not Simple
CFTR mutation identification is an important component
of newborn screening for cystic fibrosis (CF). However–
even between different individuals with the same reported
CFTRmutations–there canbewide variability to thepheno-
type,making outcomepredictions for these babies difficult,
particularly in terms of pulmonary disease. One underex-
plored issue related to this variability is the fact that CFTR
mutation analysis generally concludes when two putative
mutations have been identified on opposite alleles,
meaning that a truly complete analysis of the gene is not
performed. Lucarelli et al. wondered whether additional
variability in CFTR might influence disease outcome, and
they explored this in the context of the controversial
L997F variant of CFTR. This allele has been reported as
everything from a nonpathogenic variant to a mutation
associatedwith pulmonary disease, pancreatitis, or congen-
ital absence of the vas deferens. A comprehensive muta-
tional analysis of CFTR was completed in 12 subjects,
each of whomhad a classic CFmutation on the allele oppo-
site L997F. In the group of subjects as a whole, the CFTR-
related phenotype and sweat chloride levels varied widely.
The subset of individuals with a simple L997F allele also
exhibited a variable phenotype, but—in contrast—
a subgroup of individuals with a [R117L; L997F] complex
allele developed mild to severe CF in conjunction with
high sweat chloride levels, a narrower phenotypic rangethan the group as a whole. Similar mutational analysis of
CFTR in additional subjects may yield better predictions
of outcome in children with the L997F allele.
Lucarelli et al. (2010) Genet Med. Published online August
11, 2010. 10.1097/GIM.0b013e3181ead634.
Serum Response Factor Regulates Neovascularization
Because of its transparency and the fact that its vasculariza-
tion is tightly controlled, the cornea has been widely used
as a model of angiogenesis. In fact, angiogenesis inhibitors
have proven effective for the treatment of some types of
corneal disease. Mice that are homozygous for a null allele
of the destrin gene (Dstn) have corneal abnormalities that
include neovascularization, inflammation, and epithelial
cell hyperproliferation. A recent paper inGenetics identifies
the serum response factor (SRF) as a key downstream signal
in this pathogenic process. Abrogation of SRF expression
in the cornea of mice with corneal disease due to a lack
of destrin expression reverses their corneal disease, and it
also reduces indicators of the pathologic process. SRF has
also been implicated in the development of certain
cancers. Because angiogenesis and inflammation are
important components of cancer progression, the pathway
uncovered in this paper could have therapeutic implica-
tions beyond the eye.
Verdoni et al. (2010) Genetics. Published online August 9,
2010. 10.1534/genetics.110.117309.er 10, 2010
